A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination with Rituximab in Subjects with Treatment Naïve Marginal Zone Lymphoma

The purpose of this study is to see if the combination of Rituximab and Ibrutinib can help people with Marginal Zone Lymphoma who have not received treatment in the past. The study will also compare the combination of Rituximab and Ibrutinib with the combination of Rituximab and placebo to see which combination works better. In addition, the study will look at the safety of both combinations.